CN111991416A - 肿瘤靶向定位和递释的一氧化氮制剂 - Google Patents
肿瘤靶向定位和递释的一氧化氮制剂 Download PDFInfo
- Publication number
- CN111991416A CN111991416A CN202010828152.6A CN202010828152A CN111991416A CN 111991416 A CN111991416 A CN 111991416A CN 202010828152 A CN202010828152 A CN 202010828152A CN 111991416 A CN111991416 A CN 111991416A
- Authority
- CN
- China
- Prior art keywords
- nitric oxide
- preparation
- fluorocarbon gas
- delivery
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 title claims abstract description 161
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 56
- 238000002360 preparation method Methods 0.000 title claims abstract description 41
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 claims abstract description 31
- 239000002101 nanobubble Substances 0.000 claims abstract description 26
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims abstract description 11
- 108010020346 Polyglutamic Acid Proteins 0.000 claims abstract description 11
- 229960000502 poloxamer Drugs 0.000 claims abstract description 11
- 229920001983 poloxamer Polymers 0.000 claims abstract description 11
- 229920002643 polyglutamic acid Polymers 0.000 claims abstract description 11
- 239000002245 particle Substances 0.000 claims abstract description 10
- 239000000463 material Substances 0.000 claims abstract description 9
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical class CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims abstract description 7
- 239000003637 basic solution Substances 0.000 claims abstract description 6
- 238000005516 engineering process Methods 0.000 claims abstract description 5
- 239000012528 membrane Substances 0.000 claims abstract description 5
- 238000010253 intravenous injection Methods 0.000 claims abstract description 4
- 230000001404 mediated effect Effects 0.000 claims abstract description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 18
- 238000002156 mixing Methods 0.000 claims description 12
- 238000009472 formulation Methods 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 11
- 238000003745 diagnosis Methods 0.000 claims description 10
- 238000010438 heat treatment Methods 0.000 claims description 6
- 239000008055 phosphate buffer solution Substances 0.000 claims description 6
- 238000004321 preservation Methods 0.000 claims description 6
- 239000008344 egg yolk phospholipid Substances 0.000 claims description 5
- 229940068998 egg yolk phospholipid Drugs 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 230000009471 action Effects 0.000 claims description 4
- 230000004807 localization Effects 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 238000007789 sealing Methods 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 230000008685 targeting Effects 0.000 claims description 3
- 239000008215 water for injection Substances 0.000 claims description 3
- 239000007789 gas Substances 0.000 abstract description 32
- 210000002969 egg yolk Anatomy 0.000 abstract description 2
- 150000003904 phospholipids Chemical class 0.000 abstract description 2
- 230000000694 effects Effects 0.000 description 22
- 150000001875 compounds Chemical class 0.000 description 9
- 239000002840 nitric oxide donor Substances 0.000 description 9
- 201000007270 liver cancer Diseases 0.000 description 7
- 241000700159 Rattus Species 0.000 description 6
- 208000014018 liver neoplasm Diseases 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- 229910018503 SF6 Inorganic materials 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 229940044683 chemotherapy drug Drugs 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000037149 energy metabolism Effects 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- -1 statins Chemical class 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- WBNQDOYYEUMPFS-UHFFFAOYSA-N N-nitrosodiethylamine Chemical compound CCN(CC)N=O WBNQDOYYEUMPFS-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- YEESUBCSWGVPCE-UHFFFAOYSA-N azanylidyneoxidanium iron(2+) pentacyanide Chemical compound [Fe++].[C-]#N.[C-]#N.[C-]#N.[C-]#N.[C-]#N.N#[O+] YEESUBCSWGVPCE-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000004880 explosion Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000013022 formulation composition Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229940099578 hydrogenated soybean lecithin Drugs 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 150000002828 nitro derivatives Chemical class 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229940110728 nitrogen / oxygen Drugs 0.000 description 1
- 229960002460 nitroprusside Drugs 0.000 description 1
- XKLJHFLUAHKGGU-UHFFFAOYSA-N nitrous amide Chemical compound ON=N XKLJHFLUAHKGGU-UHFFFAOYSA-N 0.000 description 1
- QYSGYZVSCZSLHT-UHFFFAOYSA-N octafluoropropane Chemical compound FC(F)(F)C(F)(F)C(F)(F)F QYSGYZVSCZSLHT-UHFFFAOYSA-N 0.000 description 1
- 230000000174 oncolytic effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229960004065 perflutren Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- SFZCNBIFKDRMGX-UHFFFAOYSA-N sulfur hexafluoride Chemical compound FS(F)(F)(F)(F)F SFZCNBIFKDRMGX-UHFFFAOYSA-N 0.000 description 1
- 229960000909 sulfur hexafluoride Drugs 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000002476 tumorcidal effect Effects 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
- A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
- A61K49/223—Microbubbles, hollow microspheres, free gas bubbles, gas microspheres
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Engineering & Computer Science (AREA)
- Acoustics & Sound (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Radiology & Medical Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明的肿瘤靶向定位和递释的一氧化氮制剂是由基础溶液、氟碳气体微泡和一氧化氮纳米泡组成。基础溶液的组分包括聚谷氨酸和泊洛沙姆,聚谷氨酸与泊洛沙姆的质量比为1∶5。氟碳气体微泡是由氢化大豆磷脂为泡膜材料包裹氟碳气体形成的泡囊组成,粒径范围为2~5μm。一氧化氮纳米泡是由蛋黄磷脂为泡膜材料包裹一氧化氮气体形成的泡囊组成,粒径范围为300~500nm。本发明的肿瘤靶向定位和递释的一氧化氮制剂静脉注射后通过超声介导技术,实现一氧化氮的精准定位和靶向递释,用于肿瘤的高效治疗。
Description
技术领域
本发明涉及一种一氧化氮的制剂,特别涉及一种肿瘤靶向定位和递释的一氧化氮制剂。
背景技术
肿瘤(Tumour)是指机体在各种致瘤因子作用下,局部组织细胞增生所形成的新生物。随着人口老龄化的进程,肿瘤已成为危害人们生命健康最严重的疾病。
研究发现,一氧化氮(NO)与肿瘤之间存在双重关系:适当浓度的一氧化氮可促进肿瘤生长,高浓度的一氧化氮则不利于肿瘤生长而具有抗肿瘤作用。
高浓度的一氧化氮主要具有抗肿瘤作用,其机制包括:(1)介导巨噬细胞的杀肿瘤作用;(2)介导内皮细胞的溶瘤作用;(3)与细胞内的超氧阴离子结合生成氮/氧自由基,损伤DNA,从而产生细胞毒性;(4)影响细胞的能量代谢,肿瘤细胞因能量代谢障碍而死亡;(5)通过激活p53等表达而诱导肿瘤细胞发生凋亡;(6)通过抑制血小板聚集,抑制肿瘤转移;(7)增加肿瘤细胞对化疗药物的敏感性。此外,一氧化氮也广泛参与了肿瘤的化学治疗和免疫治疗过程,与化疗药物和细胞因子等相互作用,影响药物对肿瘤的杀伤作用。
已有报道的用于补充体内一氧化氮的方法多是应用一氧化氮供体化合物,例如他汀类药物,临床用于肿瘤的治疗。一氧化氮供体化合物分为两类:非酶生型和酶生型。非酶生型一氧化氮供体化合物大部分来自硝基化合物,包括硝普盐、有机或无机亚硝酸盐和硝酸盐、亚硝胺、氮芥、联氨等,剂量小且毒副作用大。而酶生型一氧化氮供体化合物(如精氨酸)需要通过体内生物酶等作用分解产生出一氧化氮分子。以上这些一氧化氮供体化合物通过体内生物酶等作用分解产生出一氧化氮分子。但是这些一氧化氮供体化合物产生的一氧化氮分子无法迅速浓集于肿瘤病灶部位起效,全身副作用较大,存在潜在安全性问题。
直接应用一氧化氮分子进行肿瘤靶向治疗,其作用发挥的最好,安全性也最高。但是一氧化氮分子是气体形态,一氧化氮气体(NO)微溶于水,在20℃的水中溶解度仅为5.6×10-3g/L(相当于0.186μmol/L),无法直接制成普通递释制剂。
因此,虽然高浓度一氧化氮对肿瘤具有很好的治疗潜力,但是一氧化氮作为气体,目前尚未见到能将一氧化氮气体高效携载于药物制剂并进行靶向递释治疗的研究报道。因此,制备高效携载一氧化氮气体的肿瘤靶向定位和递释制剂是实现一氧化氮对于肿瘤精准治疗的限制性瓶颈。
发明内容
本发明的目的在于克服现有技术的缺点(即:缺乏高效携载一氧化氮气体的肿瘤靶向定位和递释制剂)提供一种肿瘤靶向定位和递释的一氧化氮制剂,为保证一氧化氮有效治疗肿瘤提供充分的保障,同时满足临床治疗的安全、有效、便捷、经济的要求。
通过大量实验发现,本发明人发现氢化大豆磷脂为泡膜材料包裹氟碳气体形成的2~5μm微泡同时具有良好的超声造影和空化爆破作用,该氟碳气体微泡在声场中爆破后产生的空化效应,有利于开放可逆性通道,促使外源性药物快速进入肿瘤组织内部。而蛋黄磷脂为泡膜材料包裹一氧化氮气体形成的纳米泡具有很好一氧化氮储运能力,并且与机体组织亲和力强,可以借助空化效应发生体积变形,穿过比自身粒径小数十倍的孔径。但是微泡和纳米泡之间需要有足够的“黏合力”才能保证微泡产生的空化效应和纳米泡的变形递送达到完美结合。因此,本发明人通过大量实验筛选促进两者黏合的材料,发现聚谷氨酸和泊洛沙姆在一定质量比时,可以发挥最佳作用。此外,为了获得最佳抑瘤效果,氟碳气体微泡和一氧化氮纳米泡的浓度也做了大量的实验筛选,最终形成本发明的一种肿瘤靶向定位和递释的一氧化氮制剂,该制剂是由基础溶液、氟碳气体微泡和一氧化氮纳米泡组成。
上述的基础溶液的组分包括聚谷氨酸和泊洛沙姆,聚谷氨酸与泊洛沙姆的质量比为1∶5。
上述的氟碳气体微泡是由氢化大豆磷脂为泡膜材料包裹氟碳气体形成的泡囊组成。
上述的氟碳气体微泡的粒径范围为2~5μm。
上述的氟碳气体微泡在递释制剂中的浓度为6×106~9×106个/mL。
上述的一氧化氮纳米泡是由蛋黄磷脂为泡膜材料包裹一氧化氮气体形成的泡囊组成。
上述的一氧化氮纳米泡的粒径范围为300~500nm。
上述的一氧化氮纳米泡在递释制剂中的浓度为1×108~4×108个/mL。
一种上述的肿瘤靶向定位和递释的一氧化氮制剂的制备方法,包括以下步骤:
(1)氟碳气体微泡的制备:5mL甘油和45mL磷酸盐缓冲液混合,加热至65℃,加入氢化大豆磷脂,混匀后转入具塞保温耐压容器中,抽真空后注入氟碳气体,通过漩涡混合器高速振荡3min,即得氟碳气体微泡。
(2)一氧化氮纳米泡的制备:5mL甘油和45mL磷酸盐缓冲液混合,加热至65℃,加入蛋黄磷脂,混匀后转入具塞保温耐压容器中,抽真空后注入一氧化氮气体,通过漩涡混合器高速振荡3min,高压通过规定孔径筛网进行粒径均化处理,即得一氧化氮纳米泡。
(3)取质量比为1∶5的聚谷氨酸与泊洛沙姆,溶解于注射用水中,搅拌作用下分别加入上述步骤(1)和(2)制得的氟碳气体微泡和一氧化氮纳米泡,形成超声诊断和治疗肿瘤的递释制剂,15~20℃环境中密封避光保存。
上述的递释制剂静脉注射后通过超声介导技术,实现一氧化氮的精准定位和靶向递释,用于肿瘤的治疗。
本发明的肿瘤靶向定位和递释的一氧化氮制剂具有以下优点:①结合超声技术应用,发挥微泡和纳米泡之间协同作用,形成速释递送体系,起效迅速;②对于机体组织有良好的亲和性和生物相容性;③不使用任何一氧化氮供体化合物,不会因为一氧化氮供体化合物对机体组织产生不良反应和毒副作用;④静脉注射后通过超声介导技术,实现肿瘤部位的精准定位、靶向递释和治疗;⑤储存和运输便捷。
具体实施方式
下文将详细描述本发明具体实施例。应当注意的是,下述实施例中描述的技术特征或者技术特征的组合不应当被认为是孤立的,它们可以被相互组合从而达到更好的技术效果。
实施例1 肿瘤靶向定位和递释的一氧化氮制剂的制备
按照表1的组分比例,制备实验组的超声诊断和治疗肿瘤的递释制剂,具体包括以下步骤:
(1)氟碳气体微泡的制备:5mL甘油和45mL磷酸盐缓冲液混合,加热至65℃,加入氢化大豆磷脂,混匀后转入具塞保温耐压容器中,抽真空后注入表1的氟碳气体,通过漩涡混合器高速振荡3min,即得氟碳气体微泡。
(2)一氧化氮纳米泡的制备:5mL甘油和45mL磷酸盐缓冲液混合,加热至65℃,加入蛋黄磷脂,混匀后转入具塞保温耐压容器中,抽真空后注入表1的一氧化氮气体,通过漩涡混合器高速振荡3min,高压通过规定孔径筛网进行粒径均化处理,即得一氧化氮纳米泡。
(3)取质量比为1∶5的聚谷氨酸与泊洛沙姆,溶解于15倍(聚谷氨酸与泊洛沙姆总质量)的注射用水中,搅拌作用下分别加入上述步骤(1)和(2)制得的氟碳气体微泡和一氧化氮纳米泡,至表1设置的氟碳气体微泡和一氧化氮纳米泡的浓度,形成实验组的超声诊断和治疗肿瘤的递释制剂,15~20℃环境中密封避光保存。
按照表1的组分比例,对照组的制剂参照实验组进行制备。各个实验组是根据本申请权利要求项保护范围内的组分和比例配置的,而各个对照组是某项组分缺失或组分质量百分含量超出本申请权利要求项保护的范围。
表1 实验组和对照组的制剂组成
注:“/”代表该项不存在;*代表该项列名的组分被括号内的组分替代;C3F8代表全氟丙烷气体;SF6代表六氟化硫气体;NO代表一氧化氮气体;O2代表氧气;N2代表氮气。
实施例2 肿瘤靶向定位和递释的一氧化氮制剂的应用效果
(1)肝癌模型动物的建立
参考文献【改良法大鼠原发性肝癌模型的建立.中华医学杂志,2004,(23):2018-2019】,应用二乙基亚硝胺改良法建立SD大鼠原发性肝癌模型。
(2)各组递释制剂超声诊断和治疗肝癌的效果
选取肝癌建模成功的大鼠,按照表1设计平均分成若干组,每天进行给药实验,连续10天,具体为:大鼠麻醉后,通过超声成像仪将探头定位于肿瘤部位,尾静脉注射0.5mL各组递释制剂,即刻观察到肿瘤部位的影像增强后,提高声压爆破氟碳气体微泡即完成给药。第14和21天进行MRI检查,测量肿瘤体积,观察大鼠的总体状态,综合评价各组制剂对于肝癌模型动物的治疗总评分,评价结果见表2。
表2 实验组和对照组制剂对于肝癌模型动物的应用效果
由表2实验结果可见,实验组对于肿瘤的超声诊断和治疗效果较好,特别是实验组6,超声图像清晰,肿瘤体积体积基本消失,生存期很长,肿瘤的超声诊断和治疗作用很好。相比实验组,对照组对于肿瘤的超声诊断和治疗效果明显较差,特别是对照组1、2、3、11、12、13和14,对于肿瘤的治疗效果差,生存期短。
表2的实验结果证明,本发明技术保护方案中的任一组分和条件都是相互协同、缺一不可的,缺乏本发明技术保护方案中的任一组分和条件,都会对肿瘤的超声诊断和治疗效果产生明显的影响。本发明的递释制剂对于肿瘤的超声诊断和治疗效果好,具有良好的应用前景。
上述详细说明是针对发明的可行实施例的具体说明,该实施例并非用以限制本发明的专利范围,凡未脱离本发明的等效实施或变更,均应当包含于本发明的专利范围内。另外,本领域技术人员还可在本发明权利要求公开的范围和精神内做其它形式和细节上的各种修改、添加和替换。当然,这些依据本发明精神所做的各种修改、添加和替换等变化,都应包含在本发明所要求保护的范围之内。
Claims (10)
1.肿瘤靶向定位和递释的一氧化氮制剂,其主要特征在于:所述的一氧化氮制剂是由基础溶液、氟碳气体微泡和一氧化氮纳米泡组成。
2.根据权利要求1的肿瘤靶向定位和递释的一氧化氮制剂,其特征是:所述的基础溶液的组分包括聚谷氨酸和泊洛沙姆,聚谷氨酸与泊洛沙姆的质量比为1∶5。
3.根据权利要求1的肿瘤靶向定位和递释的一氧化氮制剂,其特征是:所述的氟碳气体微泡是由氢化大豆磷脂为泡膜材料包裹氟碳气体形成的泡囊组成。
4.根据权利要求1的肿瘤靶向定位和递释的一氧化氮制剂,其特征是:所述的氟碳气体微泡的粒径范围为2~5μm。
5.根据权利要求1的肿瘤靶向定位和递释的一氧化氮制剂,其特征是:所述的氟碳气体微泡在递释制剂中的浓度为6×106~9×106个/mL。
6.根据权利要求1的肿瘤靶向定位和递释的一氧化氮制剂,其特征是:所述的一氧化氮纳米泡是由蛋黄磷脂为泡膜材料包裹一氧化氮气体形成的泡囊组成。
7.根据权利要求1的肿瘤靶向定位和递释的一氧化氮制剂,其特征是:所述的一氧化氮纳米泡的粒径范围为300~500nm。
8.根据权利要求1的肿瘤靶向定位和递释的一氧化氮制剂,其特征是:所述的一氧化氮纳米泡在递释制剂中的浓度为1×108~4×108个/mL。
9.一种权利要求1的肿瘤靶向定位和递释的一氧化氮制剂的制备方法,其特征是:制备方法包括以下步骤:
(1)氟碳气体微泡的制备:5mL甘油和45mL磷酸盐缓冲液混合,加热至65℃,加入氢化大豆磷脂,混匀后转入具塞保温耐压容器中,抽真空后注入氟碳气体,通过漩涡混合器高速振荡3min,即得氟碳气体微泡;
(2)一氧化氮纳米泡的制备:5mL甘油和45mL磷酸盐缓冲液混合,加热至65℃,加入蛋黄磷脂,混匀后转入具塞保温耐压容器中,抽真空后注入一氧化氮气体,通过漩涡混合器高速振荡3min,高压通过规定孔径筛网进行粒径均化处理,即得一氧化氮纳米泡;
(3)取质量比为1∶5的聚谷氨酸与泊洛沙姆,溶解于注射用水中,搅拌作用下分别加入上述步骤(1)和(2)制得的氟碳气体微泡和一氧化氮纳米泡,形成超声诊断和治疗肿瘤的递释制剂,15~20℃环境中密封避光保存。
10.根据权利要求1所述的肿瘤靶向定位和递释的一氧化氮制剂,其特征是:所述的一氧化氮制剂静脉注射后通过超声介导技术,实现一氧化氮的精准定位和靶向递释,用于肿瘤的治疗。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010828152.6A CN111991416B (zh) | 2020-08-06 | 2020-08-06 | 肿瘤靶向定位和递释的一氧化氮制剂 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010828152.6A CN111991416B (zh) | 2020-08-06 | 2020-08-06 | 肿瘤靶向定位和递释的一氧化氮制剂 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111991416A true CN111991416A (zh) | 2020-11-27 |
CN111991416B CN111991416B (zh) | 2023-03-17 |
Family
ID=73473260
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010828152.6A Active CN111991416B (zh) | 2020-08-06 | 2020-08-06 | 肿瘤靶向定位和递释的一氧化氮制剂 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111991416B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111973731A (zh) * | 2020-08-06 | 2020-11-24 | 温州医科大学 | 冠心病靶向定位和递释的一氧化氮制剂 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140010848A1 (en) * | 2010-11-12 | 2014-01-09 | Children's Medical Center Corporation | Gas-filled microbubbles and systems for gas delivery |
US20160250252A1 (en) * | 2014-12-03 | 2016-09-01 | University Of Cincinnati | Bioactive gas-encapsulated echogenic liposomes and methods for treating cardiovascular disease |
US20180036437A1 (en) * | 2014-12-03 | 2018-02-08 | University Of Cincinnati | Gas-Encapsulated Acoustically Responsive Stabilized Microbubbles and Methods for Treating Cardiovascular Disease |
CN110237256A (zh) * | 2019-07-22 | 2019-09-17 | 重庆医科大学 | 一种载n2o微泡及其制备方法与应用 |
CN110974844A (zh) * | 2019-11-21 | 2020-04-10 | 中山大学附属第三医院 | 一种负载no的靶向微泡及其制备方法和应用 |
-
2020
- 2020-08-06 CN CN202010828152.6A patent/CN111991416B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140010848A1 (en) * | 2010-11-12 | 2014-01-09 | Children's Medical Center Corporation | Gas-filled microbubbles and systems for gas delivery |
US20160250252A1 (en) * | 2014-12-03 | 2016-09-01 | University Of Cincinnati | Bioactive gas-encapsulated echogenic liposomes and methods for treating cardiovascular disease |
US20180036437A1 (en) * | 2014-12-03 | 2018-02-08 | University Of Cincinnati | Gas-Encapsulated Acoustically Responsive Stabilized Microbubbles and Methods for Treating Cardiovascular Disease |
CN110237256A (zh) * | 2019-07-22 | 2019-09-17 | 重庆医科大学 | 一种载n2o微泡及其制备方法与应用 |
CN110974844A (zh) * | 2019-11-21 | 2020-04-10 | 中山大学附属第三医院 | 一种负载no的靶向微泡及其制备方法和应用 |
Non-Patent Citations (3)
Title |
---|
KUN ZHANG等: "Ultrasound-Triggered Nitric Oxide Release Platform Based on Energy Transformation for Targeted Inhibition of Pancreatic Tumor", 《ACS NANO》 * |
MAXIME LAFOND等: "Bactericidal Activity of Lipid-Shelled Nitric Oxide-Loaded Microbubbles", 《FRONTIERS IN PHARMACOLOGY》 * |
SAMANTHA M. FIX等: "Therapeutic gas delivery via microbubbles and liposomes", 《JOURNAL OF CONTROLLED RELEASE》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111973731A (zh) * | 2020-08-06 | 2020-11-24 | 温州医科大学 | 冠心病靶向定位和递释的一氧化氮制剂 |
CN111973731B (zh) * | 2020-08-06 | 2023-03-24 | 温州医科大学 | 冠心病靶向定位和递释的一氧化氮制剂 |
Also Published As
Publication number | Publication date |
---|---|
CN111991416B (zh) | 2023-03-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Lin et al. | Ultrasound activation of liposomes for enhanced ultrasound imaging and synergistic gas and sonodynamic cancer therapy | |
Yang et al. | Focused ultrasound and interleukin-4 receptor-targeted liposomal doxorubicin for enhanced targeted drug delivery and antitumor effect in glioblastoma multiforme | |
Wang et al. | Integration of cascade delivery and tumor hypoxia modulating capacities in core-releasable satellite nanovehicles to enhance tumor chemotherapy | |
Yang et al. | Lipid microbubbles as ultrasound-stimulated oxygen carriers for controllable oxygen release for tumor reoxygenation | |
Matsuki et al. | Blood oxygenation using microbubble suspensions | |
Song et al. | pH-responsive oxygen nanobubbles for spontaneous oxygen delivery in hypoxic tumors | |
Miller et al. | Lithotripter shock waves with cavitation nucleation agents produce tumor growth reduction and gene transfer in vivo | |
CN107952072B (zh) | 载药载氧杂交蛋白纳米粒的制备方法、载药载氧杂交蛋白纳米粒和应用 | |
CN113101269B (zh) | 一种基于纳米脂质体的递送系统、制备方法及应用 | |
CN111991416B (zh) | 肿瘤靶向定位和递释的一氧化氮制剂 | |
Guo et al. | Self-assembled peptide nanoparticles with endosome escaping permits for co-drug delivery | |
CN113509551A (zh) | 一种槲皮素铁离子胶束及其在肿瘤光热免疫治疗中的应用 | |
US11793983B2 (en) | Sonodynamic therapy using microbubbles and pulsed wave ultrasound methods and systems | |
Cui et al. | A novel ligand-modified nanocomposite microparticles improved efficiency of quercetin and paclitaxel delivery in the non-small cell lung cancer | |
CN105327358A (zh) | 一种联合输送核酸与多肽的纳米制剂及制备方法 | |
Khan et al. | Effective delivery of mycophenolic acid by oxygen nanobubbles for modulating immunosuppression | |
CN111973731B (zh) | 冠心病靶向定位和递释的一氧化氮制剂 | |
Deng et al. | Targeted H+-triggered bubble-generating nanosystems for effective therapy in cancer cells | |
CN111840583B (zh) | 血管内皮损伤治疗的药物制剂 | |
JP2005255582A (ja) | 光照射を用いた遺伝子または薬物導入発現方法 | |
CN111973623B (zh) | 心力衰竭靶向治疗的速释制剂 | |
Song et al. | Development of Nano Oxygen Carrier for Enhanced Cancer Therapy | |
CN113975248B (zh) | 肝癌靶向诊疗一体化的纳米颗粒及其应用 | |
Truong Hoang et al. | Oxygen‐Supplying Piezocatalytic Therapy of Hypoxic Tumors by Intratumoral Delivery of pH‐Responsive Multicompartmental Carriers with Sequential Drug Release Capability | |
Yu et al. | Mitochondria-targeted carrier-free nanoparticles based on dihydroartemisinin against hepatocellular carcinoma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |